Bevacizumab biosimilar - Hetero Drugs

Drug Profile

Bevacizumab biosimilar - Hetero Drugs

Alternative Names: Cizumab

Latest Information Update: 13 Jul 2016

Price : $50

At a glance

  • Originator Hetero Drugs
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer

Most Recent Events

  • 11 Jul 2016 Launched for Colorectal cancer (First-line therapy, Metastatic disease) in India (IV)
  • 27 Jun 2016 Registered for Colorectal cancer (First-line therapy, Metastatic disease) in India (IV) before June 2016
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top